Related references
Note: Only part of the references are listed.Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Peter Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors A Systematic Review and Meta-analysis
Nicolas Delanoy et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2015)
Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia
Prahlad Ho et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches
Osamu Matsuno
RESPIRATORY RESEARCH (2012)
Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman
Bushra M Ahmed et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2012)
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M. Evens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects
Joseph R. Carver et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
WG Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Delayed onset bleomycin-induced pneumonitis
I Uzel et al.
UROLOGY (2005)
Bleomycin lung toxicity: who are the patients with increased risk?
E Azambuja et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2005)
Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity
K Adachi et al.
TOXICOLOGIC PATHOLOGY (2003)
Share Paper
